

Minutes of Pre-bid meeting for Supply of Artesunate Injection Kit against: IFB No. RITES/MSM/EPW/NVBDCP/02/2013 held on 04.03.2013 at 14:00 hrs at RITES office complex - II.

1. The following were present:-

I) From RITES:

Shri V. K. Langan, GM/NVBDCP - In Chair
 Shri P. V. Dutta, AM/MSM
 Shri Anil Gupta, Pharma Expt./MSM
 Ms. Neeru D Sandhu, Proc. Expt./NVBDCP

II) Firms which attended the Pre-bid conference are as follows:

<u>S.No.</u>	<u>Name of representative (Shri)</u>	<u>Name of Firm</u>
1.	S.K.Wadhawan	M/s IPCA Labs Ltd., New Delhi
2.	Arun Sharma	M/s Hospimax Healthcare Pvt. Ltd., New Delhi

2. Initiating the discussion, chairperson welcomed the participants. It was explained that purpose of Pre-bid meet is to educate the bidders regarding various important provisions of the bidding documents and also to clarify any queries that the bidders may have in the subject bidding documents.

3. The issues raised during the pre bid meeting and clarifications are as under :

<u>S No.</u>	<u>Query Raised by bidders</u>	<u>Clarifications</u>
1.	<p>Refer Section VII Technical Specifications, Page 107 (F. Shelf Life of Artesunate Injection Kit)</p> <p>Shelf Life: 36 months</p> <p>Firm's request:- "2 years".</p>	<p>Agreed. Please refer Amendment no. 2.</p>
2.	<p>Refer Section II Bid Data Sheet, Page 40 (ITB 7.1 (a))</p> <p>For the schedules funded by GFATM, an additional requirement is as follows:-</p> <p>The selection of supplier will be as per Global Fund Quality Assurance Policy, as applicable on the date of bid opening. Bidders should submit the relevant documentary evidence in support. Reference may be made to the GFATM website. http://www.theglobalfund.org/en/procurement/pharmaceutical/?lang=en</p> <p>The bidder shall either be prequalified by the World Health Organization (WHO) for the product being offered or products being offered by the bidder should be approved (or tentatively approved) or authorized for use by a stringent regulatory authority (a member, observer or associate of ICH) as per GFATM QA policy and the prequalification/approval or authorization will be valid on the date of</p>	<p>The schedules financed by GFATM have been deleted Please refer Amendment no. 2.</p>

<u>S No.</u>	<u>Query Raised by bidders</u>	<u>Clarifications</u>
	<p>submission of bid.</p> <p>Firm's request: - <i>"No Indian manufacture having prequalification with WHO. Hence remove this clause".</i></p>	
3.	<p>Refer Section VII Technical Specifications, Disposable Syringe & disposable Needle (pg 103), Quality Assurance (pg 105)</p> <p>Syringe: Manufacturer should fulfill GFATM clause & shall also confirm to the standards given in IS 10258:2002 & manufacturing facility must confirm to ISO 13485 & Schedule M-III of Drug & cosmetic act.</p> <p>Needle: Manufacturer should confirm the standard given in IS 10654:2002 & color coded as per requirement of ISO 6009 & manufacturing facility must confirm to ISO 13485 & Schedule M-III of Drug & cosmetic act.</p> <p>Firm's request : - <i>"Since we have to procure the Syringe and Needle from the manufacturer & no manufacturer is prequalified as asked by GFATM clause. They can provide us only ISO-13485. Hence we can supply the product confirm to ISO -13485".</i></p>	<p>The schedules financed by GFATM have been deleted. Please refer Amendment no. 2.</p>